Design and validation of standardized clinical and functional remission criteria in schizophrenia

Neuropsychiatric Disease and Treatment

Volumn 10, Issue , 2014, Pages 167-181

  Mosolov, Sergey N ^a   Potapov, Andrey V ^a   Ushakov, Uriy V ^b   Shafarenko, Aleksey A ^a   Kostyukova, Anastasiya B ^a  

^a Moscow Research Institute of Psychiatry   (Russian Federation)

^b Moscow Outpatient Psychiatric Service 21   (Russian Federation)

Author keywords

Long acting risperidone (RLAI); PANSS; PSP; Remission criteria; Schizoaffective disorder; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ADULT; ARTICLE; CONTROLLED CLINICAL TRIAL (TOPIC); FEMALE; FOLLOW UP; GLOBAL ASSESSMENT OF FUNCTIONING; HUMAN; INTERNATIONAL REMISSION CRITERIA; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PARANOID SCHIZOPHRENIA; PERSONAL AND SOCIAL PERFORMANCE SCALE; POSITIVE AND NEGATIVE SYNDROME SCALE; PSYCHOLOGIC TEST; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RUSSIAN FEDERATION; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SOCIAL INTERACTION; STANDARDIZED CLINICAL AND FUNCTIONAL REMISSION CRITERIA;

EID: 84893447997     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S46799     Document Type: Article

References (44)

1. Andreasen NC, Carpenter WT Jr, Kane JM, et al. Remission in schizophrenia: proposed criteria and rational for consensus Am. J. Psychiatry. 2005;162:441-449.
2. Liberman RP, Kopelowicz A, Venture J, Gutkind D. Operational criteria and factors related to recovery from schizophrenia. Int Rev Psychiatry. 2002;14(4):256-272.
3. EUFAMI-Remission in schizophrenia-related survey, 2007, Oct. Available from: http://www.eufami.org/images/eufami/main/file/syrvey/%20press%20-%20final.pdf.
4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders-DSM-IV-TR. 4th edition. Arlington, VA: American Psychiatric Association; 2000.
5. World Health Organization: The ICD-10. Chapter 5. Classification of Mental and Behavioural Disorders. 10th edition. World Health Organization. Geneva-1994. Available from: http://www.who.int/classifications/icd.
6. Kotsyubinsky AP, Skorik AI, Aksenova IO, et al. Schizophrenia: vulnerability-stress-diathesis-disease.-Saint-Petersburg: Hippocrates+, 2004; p. 88-109. Russian.
7. Melekhov DE. Clinical basis for work capacity forecast in schizophrenia. Moscow, Russia. MedGiz. 1963:198. Russian.
8. Morozov VM. Remissions in schizophrenia and work and disability expertise questions. Zhurnal Nevrologii. i Psihiatrii S S Korsakov.1953;10:770-774. Russian.
9. Sverdlov LS. Clinico-psychopathological and clinico-psychological analyses of therapeutic remissions in acute schizophrenia episodes. Biological therapy in rehabilitation system of mentally ill patients. Leningrad, Russia. Meditsina. 1980:48-60. Russian.
10. Vovin R Ya. Remission dynamics in schizophrenia and rational psychopharmacotherapy. Prophylactic and antirecidive therapy of mental diseases. Leningrad. Meditsina. 1986:5-16. Russian.
11. Zenevich GV. Remissions in Schizophrenia. Leningrad, Russia. Meditsina. 1964:216. Russian.
12. Smulevich AB, Andrutshenko AN, Beskova DA. The problem of remission in schizophrenia: clinical and epidemiological study. Zh Nevrol Psikhiatr Im S S Korsakova. 2007;107(5):4-15. Russian.
13. Kay SR, Fizbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276.
14. Liddle PF. The symptoms of chronic schizophrenia. A reexamination of the positive-negative dichotomy. Br J Psychiatry. 1987;151: 145-151.
15. Docherty JP, Bossie CA, Lachaux B, et al. Patient-based and clinician-based support for the remission criteria in schizophrenia. Int Clin Psychopharmacol. 2007;22(1):51-55.
16. Haro JM, Novick D, Suarez D, Alonso J, Lépine JP, Ratcliffe M; SOHO Study Group. Remission and relapse in the outpatient care of schizophrenia: three-year results from the Schizophrenia Outpatients Health Outcomes Study. J Clin Psychopharmacol. 2006;26(6):571-578.
17. Helldin L, Kane JM, Karilampi U, Norlander T, Archer T. Remission and cognitive ability in a cohort of patients with schizophrenia. J Psychiatry Res. 2006;40(8):738-745.
18. Leucht S, Beitinger R, Kissling W. On the concept of remission in schizophrenia. Psychopharmacology (Berl). 2007;194(4):453-461.
19. Li CT, Su TP, Chou YH, et al. Symptomatic resolution among Chinese patients with schizophrenia and associated factors. J Formos Med Assoc. 2010;109(5):378-388.
20. Buckley PF, Harvey PD, Bowie CR, Loebel A. The relationship between symptomatic remission and neuropsychological improvement in schizophrenia patients switched to treatment with ziprasidone. Schizophr Res. 2007;94(1-3):99-106.
21. De Hert M, van Winkel R, Wampers M, Kane J, van Os J, Peuskens J. Remission criteria for schizophrenia: evaluation in a large naturalistic cohort. Schizophr Res. 2007;92(1-3):68-73.
22. Gorwood P, Peuskens J; European Group On Functional Outcomes, Remission in Schizophrenia. Setting new standards in schizophrenia outcomes: symptomatic remission 3 years before versus after the Andreasen criteria. Eur Psychiatry. 2012;27(3):170-175.
23. Kane JM, Crandall DT, Marcus RN, et al. Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks. Schizophr Res. 2007;95(1-3):143-150.
24. Kurihara T, Kato M, Reverger R, Tirta IG. Remission in schizophrenia: a community-based 6-year follow-up study in Bali. Psychiatry Clin Neurosci. 2011;65(5):476-482.
25. Mosolov SN, Potapov AV, Ushakov UV. Remission in schizophrenia: results of cross-sectional with 6-month follow-up period and 1-year observational therapeutic studies in an outpatient population. Ann Gen Psychiatry. 2012;11(1):1 doi: 10.1186/1744-859X-11-1.
26. San L, Ciudad A, Alvarez E, Bobes J, Gilaberte I. Symptomatic remission and social/vocational functioning in outpatients with schizophrenia: prevalence and associations in a cross-sectional study. Eur Psychiatry. 2007;22(8):490-498.
27. van Os J, Drukker M, Campo J, Meijer J, Bak M, Delespaul P. Validation of remission criteria for schizophrenia. Am J Psychiatry. 2006;163(11):2000-2002.
28. Wunderink L, Sytema S, Nienhuis FJ, Wiersma D. Clinical recovery in first-episode psychosis. Schizophr Bull. 2009;35(2):362-369.
29. Wolter A, Preuss UW, Krischke NR, Wong WM, Zimmermann J. Remission, prediction and stability of symptoms in schizophrenia: A naturalistic 12-month follow-up study. Int J Psychiatry Clin Pract. 2010;14(3):160-167.
30. Zimmermann J, Wolter A, Krischke NR, Preuss UW, Wobrock T, Falkai P. Response and remission in schizophrenic subjects. Nervenarzt. 2011;82(11):1440-1448. German.
31. Levine SZ, Rabinowitz J, Ascher-Svanum H, Faries DE, Lawson AH. Extent of attaining and maintaining symptom remission by antipsychotic medication in the treatment of chronic schizophrenia: evidence from the CATIE study. Schizophr Res. 2011;133(1-3):42-46.
32. Lasser RA, Bossie CA, Gharabawi GM, Kane JM. Remision in schizophrenia: Results from a 1-year study of long-acting risperidone injection. Schizophr Res. 2005;77(2-3):215-227.
33. Mosolov SN, Potapov AV, Dediurina IUM, Ushakov UV, Tsukarzi EE. The validation of international criteria for remission in schizophrenia in the outpatient population. Zh Nevrol Psikhiatr Im S S Korsakova. 2010;110(5):71-75. Russian.
34. Wobrock T, Köhler J, Klein P, Falkai P. Achieving symptomatic remission in out-patients with schizophrenia-a naturalistic study with quetiapine. Acta Psychiatr Scand. 2009;120(2):120-128.
35. Eberhard J, Levander S, Lindström E. Remission in schizophrenia: analysis in a naturalistic setting. Compr Psychiatry. 2009;50(3): 200-208.
36. Lambert M, Schimmelmann BG, Naber D, et al. Prediction of remission as a combination of symptomatic remission and adequate subjective well-being in 2960 patients with schizophrenia. J Clin Psychiatry. 2006;67(11):1690-1697.
37. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59 Suppl 20:22-33.
38. Mosolov SN. Scales of psychometric assessment in schizophrenia and conception of positive and negative syndromes, Moscow, Russia, Novy Tsvet, 2001. Russian.
39. Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand. 2000;101(4):323-329.
40. Weiden P, Rapkin B, Mott T, et al. Rating of medication influences (ROMI) scale in schizophrenia. Schizophr Bull. 1994;20(2): 297-310.
41. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11-19.
42. Lambert M, Karow A, Leucht S, Schimmelmann BG, Naber D. Remission in schizophrenia: validity, frequency, predictors, and patients' perspective 5 years later. Dialogues Clin. Neurosci. 2010; 12(3):393-407.
43. Emsley R, Chiliza B, Asmal L, Lehloenya K. The concepts of remission and recovery in schizophrenia. Curr Opin Psychiatry. 2011;24(2): 114-121.
44. Hare RD. A research scale for the assessment of psychopathy in criminal populations. Personality and Individual Differences. 1980;1(2):111-119. Available from: http://dx.doi.org/10.1016/0191-8869(80)90028-8. Accessed January 6, 2014.